Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atenativ in early and severe preeclampsia with low antithrombin activity
2012-005770-57Phase 4Active
- Sponsor
- Sahlgrenska University Hospital
- Start
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of antithrombin III concentrate in preeclampsia, sponsored by Sahlgrenska University Hospital. Primary endpoints: Uterine artery blood flow during Atenativ infusion and Amount of Atenativ required to maintain normal antithrombin activity. Started Dec 2012; status: active.
02
Drugs
antithrombin III concentrate
03
Conditions
preeclampsia
Beyond the preview
Go deeper on 2012-005770-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005770-57.